PICICI direct

CMP: ₹ 503 Target: ₹ 530 (5%) Target

Target Period: 12 months

May 6, 2022

Sticky inflation to elongate margin recovery...

About the stock: Marico is one of the major FMCG companies present in hair oil, edible oil, foods & personal care segment. Major brands include Parachute, Saffola, Nihar, Hair & Care, Set Wet, Livon & Beardo.

- Marico has an overall distribution network of more than 5 million outlets and direct reach of ~1 million outlets. Through its stockist network, it reaches 58000 villages
- With high gross margins of 45-50%, the company is able to spend 8-9% of its sales on advertisements to support new categories and products

Q4FY22 Results: Marico posted decent results with 7.4% sales growth.

- Sales were up 7.4% YoY largely contributed by pricing; 1% volume growth
- EBITDA was at ₹ 346 crore, up 8.5% YoY, margins at 16% (up 16 bps)
- PAT was at ₹ 256.9 crore (up 13.2% YoY)

What should investors do? Marico's share price has given 60% return in the last five years (from ₹ 314 in May 2017 to ₹ 503 in May 2022).

- We cut our margin estimates due to high inflation in edible oils, crude derivatives
- We change our rating on the stock from BUY to HOLD rating

Target Price and Valuation: We value the stock at ₹ 530 on ascribing 45x FY24 earnings multiple.

Key triggers for future price performance:

- Robust growth in foods led by tailwinds of healthy eating habits. Foods portfolio reported ₹ 450+ crore sales in FY22
- Market share gains in Parachute given smaller, regional brands find it difficult to pass on sharp commodity price fluctuations (up or down)
- Incessant commodity inflation in edible oil, crude based derivatives like HDPE, liquid paraffin to keep margins below normalised levels of 19%
- Investing in digital only brands. Aims to achieve ₹ 500 crore sales by FY24

Alternate Stock Idea: We like Dabur in our FMCG coverage.

- Significant shift in consumption towards healthier, natural & Ayurveda based products and aggressively foray in many big categories would be driving growth for Dabur
- Value the business at 52x FY24 earnings. BUY with a TP of ₹ 680

HOLD



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	64,929.3
Total Debt (FY22)	345.0
Cash and Investments (FY22)	1,220.0
EV	64,054.3
52 week H/L (₹)	606 / 455
Equity capital	129.0
Face value (₹)	1.0

Shareholding pattern											
(in %)	Jun-21	Sep-21	Dec-21	Mar-22							
Promoter	59.6	59.5	59.5	59.5							
FII	25.0	25.9	25.6	25.1							
DII	9.7	8.6	8.6	8.8							
Others	5.7	6.0	6.4	6.6							
DII	9.7	8.6	8.6	8							



Recent event & key risks

- Launched peanut butter & mayonnaise under Saffola Brand
- Key Risk: (i) Incessant inflation in crude based RM to pressurise margins (ii) Strong agri exports can significantly improve consume sentiment

Research Analyst

Sanjay Manyal sanjay.manyal@icicisecurities.com

Key Financial Summary							
				5 Year CAGR			
Key Financials	FY20	FY21	FY22	(FY17 to FY22)	FY23E	FY24E	CAGR (FY22-24E)
Net Sales	7315.0	8048.0	9512.0	9.9	10371.2	11138.9	8.2%
EBITDA	1469.0	1591.0	1681.0	7.7	1896.6	2103.2	11.9%
EBITDA Margin %	20.1	19.8	17.7		18.3	18.9	
Net Profit	1043.0	1199.0	1254.9	9.1	1364.0	1511.7	9.8%
Adjusted Net Profit	1043.0	1199.0	1254.9	9.1	1364.0	1511.7	9.8%
EPS (₹)	8.08	9.29	9.73		10.57	11.72	
P/E	62.3	54.2	51.7		47.6	43.0	
RoNW %	34.5	37.0	37.5		41.4	47.4	
RoCE (%)	41.0	40.3	41.2		46.8	52.9	

Source: Company, ICICI Direct Research



Key takeaways of recent quarter

Q4FY22 Results: Margins still below historic averages; volumes growth remains dismal due to rural slowdown

- Marico reported 7.4% revenue growth to ₹ 2161 crore led by 5.1% growth in India business and 12% constant currency growth in international business. The growth in both domestic & international business was largely driven by price hikes taken in the last one year to pass on steep commodity inflation. Domestic volume growth was 1% during the quarter on a relatively high base of 25% growth. On a full year basis, volume growth was 7%
- Parachute (rigid pack) volumes de-grew 1% in Q4 on a high growth of 29% in base quarter. On a full year basis, value growth was 11% aided by 5% volume growth. We believe the company would have taken 5-10% price cuts in Parachute Coconut oil portfolio either through change in MRPs or consumer & trade promotions. This would have led to value de-growth in Parachute (rigid pack) in Q4. However, the company gained market share by 170 bps in FY22
- VAHO segment witnessed 3% value growth with similar volume growth during the quarter. The company has not taken any price hikes in the segment in the last one year. It has gained market share by 90 bps in Q4. It saw 14% value and volume growth during the year
- Saffola edible oil saw 17% value growth & flat volumes in Q4 as well as for the year. Steep inflation in edible oils has impacted volumes in the segment.
 We believe higher edible oil prices leads to down-trading to the regional, economy brands
- Saffola foods portfolio witnessed growth of 17% during the quarter even on a high base. It saw 50% value growth for the year. Foods portfolio clocked more than ₹ 450 crore of sales in FY22. Saffola Oats brand gained 512 bps market share with 42% value market share in FY22
- Saffola Honey & Saffola Mealmaker Soya chunks clocked ₹ 50-100 crore sales in first year of launch. The company launched Peanut Butter & Saffola Mayonnaise during the quarter at the e-commerce & online channel. The company would expand these brands in the offline channels as well
- With the expansion in multiple foods category under Saffola brand, total addressable market would be close to ₹ 6000 crore. The company would continue to expand in medium size food categories, which are largely urban centric. Marico is targeting sales of ₹ 850-1000 crore for Saffola Foods by FY24
- Premium personal care grew in double digit in FY22. Livon clocked double digit growth on a YoY basis, digital brands 'Beardo' has crossed ₹ 100 crore annual run rate on exit basis. Just Herbs has also met internal targets. Digital-first brands have delivered ₹ 180-200 crore run rate on an exit basis. The company plans to build a ₹ 450-500 crore portfolio by FY24
- In international business, Bangladesh, Vietnam, South Africa and MENA regions delivered constant currency growth of 16%, 7%, 20% and 11%, respectively. For FY22, revenue growth was 14%, 12%, 18% and 27%, respectively
- In the near term, due to inflationary headwinds, demand is expected to be uncertain. Hence, margins are expected to remain subdued. Both demand and margins are expected to improve from the second half of FY23
- With the stabilisation of copra prices & sharp price increase taken in Saffola edible oil last one year, gross margins were up 33 bps. Copra prices were down 9% YoY whereas rice-bran, liquid paraffin (LLP) & HDPE prices were up 26%, 9% & 19%, respectively. The employee spends were down (percentage to sales) by 102 bps whereas marketing & overhead spends increased 84 bps and 36 bps, respectively



- Operating profit grew 8.5% to ₹ 346 crore with 16 bps improvement in operating margins. However, operating margins are much lower than historical averages. Net profit saw growth of 13.2% to ₹ 256.9 crore
- The company increased advertisement spends to 9.4% of sales for the quarter. This is mainly to support core as well as new brands despite inflationary pressure adversely impacting margins
- In the medium term, the company aspires to grow revenue at 13-15% with 8-10% volume growth. It is targeting 5-7% volume growth in Parachute, double digit value growth in VAHO & high single digit volume growth in Saffola edible oil
- In the international business, the company expects to grow revenues in double digits with a stable geo-political environment
- Net working capital for the company improved from 19 days in FY21 to 12 days in FY22

Exhibit 1: Peer Comp	Exhibit 1: Peer Comparison																		
Sector / Company	CMP	TP		M Cap	Sales	growt	h (%)	EBITD A	\ Margi	ns (%)		P/E(x)		- 1	RoE (%)		R	oCE (%)
	(₹)	(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Hindustan Unilever (HINLEV)	2149	2200	Hold	503770	11.3	9.8	7.5	24.8	24.3	24.7	57.1	54.3	49.1	18.1	19.1	21.2	20.2	21.9	24.2
Dabur India (DABIND)	511	680	Buy	93515	13.9	10.2	11.2	20.7	20.5	20.9	53.7	45.6	40.6	20.8	22.5	22.8	24.9	25.5	26.4
Tata Consumer (TATGLO)	765	910	Buy	71514	7.1	9.7	9.7	13.8	15.6	16.1	70.4	51.8	44.4	7.0	8.8	9.8	8.4	10.3	11.3
Marico (MARLIM)	503	530	Hold	64929	18.2	9.0	7.4	17.7	18.3	18.9	51.7	47.6	43.0	37.5	41.4	47.4	41.2	46.8	52.9

Source: Company, ICICI Direct Research

Marico was impacted by high copra prices in FY21 and H1FY22. With the decline in copra prices in the last two quarters, gross margins were expected to improve considerably and return normal level of ~19%. However, incessant inflation in edible oil & crude derivative prices has adversely impacted gross margins & the subsequent expected improvement in operating margin trajectory. Similar to all other FMCG companies, volume growth was dismal due to adverse consumer sentiments specifically in rural & semi-urban regions. A sharp rise in edible oils is leading to down-trading towards economy brands. The only growth category for the company remains foods business, which has grown at 17% despite a high base. The company has achieved its ₹ 450 crore + sales target for the foods business in FY22. Going forward, we remain cautious on the volume growth trajectory as well as recovery in operating margins to normalised levels. We value the stock at 45x FY24 earnings with a target price of ₹ 530/share (earlier ₹ 550) and a **HOLD** recommendation.



Exhibit 2: Variance Ar	nalysis						
	Q4FY22	Q4FY22E	Q4FY21	YoY (%)	Q3FY22	QoQ (%)	
Net Sales	2,161.0	2,193.8	2,012.0	7.4	2,407.0	-10.2	Net sales witnessed growth of 7.4% led by 6.4% price hikes & 1% volume growth
Raw Material Expenses	1,200.0	1,227.2	1,124.0	6.8	1,355.0	-11.4	Gross margins improved 33 bps on account of 9% dip in copra prices. However, rice-bran oil & crude based commodities still reamained elevated
Employee Expenses	139.0	163.9	150.0	-7.3	144.0	-3.5	The company was able to save 106 bps (percentage to sales) through a reduction in employee spends
SG&A Expenses	204.0	209.8	173.0	17.9	223.0	-8.5	It increased marketing spends to support volume growth in new $\boldsymbol{\vartheta}$ existing categories
Other operating Expenses	272.0	256.4	246.0	10.6	254.0	7.1	
EBITDA	346.0	336.5	319.0	8.5	431.0	-19.7	
EBITDA Margin (%)	16.0	15.3	15.9	16 bps	17.9	-190 bps	Operating margins were slightly up by 16 bps. However, it still remains much lower than its usual range of 18-19%
Depreciation	37.0	36.7	36.0	2.8	36.0	2.8	
Interest	11.0	10.2	10.0	10.0	10.0	10.0	
Other Income	24.0	21.9	29.0	-17.2	22.0	9.1	
Exceptional items	0.0	0.0	-19.0	NA	0.0	NA	
Minority Interest	0.0	-2.0	0.0	NA	0.0	NA	
PBT	321.9	309.4	283.0	13.8	407.0	-20.9	
Tax Outgo	65.0	68.4	56.0	16.1	90.0	-27.8	
PAT	256.9	240.9	227.0	13.2	317.0	-18.9	Net profit grew 13.2% led by growth in operating profit and lower tax provisioning in ${\tt Q4}$

Source: Company, ICICI Direct Research

Exhibit 3: Change in estimates											
		FY23E			FY24E						
(₹ Crore)	Old	New	% change	Old	New ?	6 change	Comments				
Revenues	10,416.6	10,371.2	-0.4	11,188.3	11,138.9	-0.4	No major change in our revenue estimates				
EBITDA	2,044.1	1,896.6	-7.2	2,215.2	2,103.2	-5.1					
EBITDA Margin (%)	19.6	18.3	-134 bps	19.8	18.9	-92 bps	Despite fall in copra prices, we are cutting our operating margins estimates due to incessant inflation in edible oils, liquid parafins & other crude related derivatives, which can continue to impact margins in the next two to three quarters				
PAT	1,471.9	1,364.0	-7.3	1,592.6	1,511.7	-5.1					
EPS (₹)	11.4	10.6	-7.3	12.3	11.7	-5.1					

Source: ICICI Direct Research

Exhibit 4: Assumptions											
			Currer	nt		Earlier					
	FY19	FY20	FY21E	FY22E	FY23E	FY24E	FY23E	FY24E	Comments		
Std. Sales (₹ crore)	5,756.0	5,853.0	6,337.0	7,500.0	8,158.0	8,726.5	8,158.0	8,726.5	Small change in our international sales estimates		
Subs. Sales (₹ crore)	1,578.0	1,462.0	1,711.0	2,012.0	2,213.2	2,412.4	2,183.2	2,379.7	,		

Source: ICICI Direct Research


Key Metrics

Exhibit 5: Revenue to grow at 8.2% CAGR over FY22-24E



Source: ICICI Direct Research, Company

Exhibit 6: Domestic volume trend YoY (%)




Source: ICICI Direct Research, Company

Exhibit 7: EBITDA margin and raw material trend



Source: Company, ICICI Direct Research

Exhibit 8: PAT (₹ crore) – LHS and PAT growth YoY (%) - RHS



Source: Company, ICICI Direct Research

Exhibit 9	Exhibit 9: Valuation											
	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE				
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)				
FY21	8048.0	10.0	9.3	15.0	54.2	40.1	37.0	40.3				
FY22	9512.0	18.2	9.7	4.7	51.7	38.1	37.5	41.2				
FY23E	10371.2	9.0	10.6	8.7	47.6	33.8	41.4	46.8				
FY24E	11138.9	7.4	11.7	10.8	43.0	30.6	47.4	52.9				

Source: Company, ICICI Direct Research



Financial Summary

Exhibit 10: Profit and loss sta	tement			₹ crore
(Year-end March)	FY21	FY22	FY23E	FY24E
Total Operating Income	8048.0	9512.0	10371.2	11138.9
Growth (%)	10.0	18.2	9.0	7.4
Raw Material Expenses	4,270.0	5,436.0	5,757.4	6,084.0
Employee Expenses	570.0	586.0	674.1	735.2
Marketing Expenses	698.0	796.0	933.4	1,013.6
Excise Duty	0.0	0.0	0.0	0.0
Other expenses	919.0	1,013.0	1,109.7	1,203.0
Total Operating Expenditure	6,457.0	7,831.0	8,474.6	9,035.8
EBITDA	1591.0	1681.0	1896.6	2103.2
Growth (%)	8.3	5.7	12.8	10.9
Depreciation	139.0	139.0	157.9	172.3
Interest	34.0	39.0	45.8	47.8
Other Income	94.0	98.0	101.9	106.0
Share of profit/(loss) of associates	0.0	0.0	0.0	0.0
Total Tax	324.0	346.0	430.7	477.4
PAT	1188.0	1255.0	1364.0	1511.7
Growth (%)	10.8	5.6	8.7	10.8
Adjusted PAT	1199.0	1254.9	1364.0	1511.7
Adjusted EPS (₹)	9.3	9.7	10.6	11.7

Exhibit 11: Cash flow state	ement			₹ crore
(Year-end March)	FY21	FY22	FY23E	FY24E
Profit before Tax	1,523.0	1,601.0	1,794.8	1,989.1
Add: Depreciation	139.0	139.0	157.9	172.3
(Inc)/dec in Current Assets	480.0	-542.0	-129.1	-288.8
Inc/(dec) in CL and Provisions	250.0	200.0	-35.4	124.6
Others	-324.0	-382.0	-430.7	-477.4
CF from operating activities	2,068.0	1,016.0	1,357.5	1,519.9
(Inc)/dec in Investments	-664.0	615.0	-52.0	-52.0
(Inc)/dec in Fixed Assets	-274.0	-187.0	313.9	42.3
Others	0.0	0.0	-127.9	-142.3
CF from investing activities	-938.0	428.0	134.0	-152.0
Issue/(Buy bick) of Equity	6.0	41.0	0.0	0.0
Inc/(dec) in loan funds	-170.0	-133.0	-2.0	-2.0
Dividend paid & dividend tax	-968.0	-1,195.0	-1,419.0	-1,612.5
CF from financing activities	-1,119.0	-1,290.0	-1,421.0	-1,614.5
Net Cash flow	16.0	156.0	70.5	-246.6
Opening Cash	93.0	109.0	276.0	346.5
Cash in Bank	835.0	303.0	303.0	303.0
Closing Cash	944.0	579.0	649.5	402.9

Source: Company, ICICI Direct Research

Exhibit 12: Balance Sheet				₹ crore
(Year-end March)	FY21	FY22	FY23E	FY24E
Liabilities				
Share Capital	129.0	129.0	129.0	129.0
Reserve and Surplus	3,111.0	3,219.0	3,164.0	3,063.2
Total Shareholders funds	3,240.0	3,348.0	3,293.0	3,192.2
Long Term Borrowings	0.0	0.0	0.0	0.0
Provisions & other LTL	130.0	91.0	91.0	91.0
Minority Interest / Others	18.0	57.0	57.0	57.0
Deferred Tax Liability	109	137	135	133
Total Liabilities	3497.0	3633.0	3576.0	3473.2
Assets				
Gross Block	1,136.0	1,256.0	1,376.0	1,496.0
Less: Acc Depreciation	603.0	742.0	899.9	1,072.2
Net Block	769.0	800.0	476.1	423.8
Capital WIP	24.0	39.0	49.0	59.0
Goodwill on Consolidation	613.0	654.0	624.0	594.0
Non Current Investments	271.0	208.0	233.0	258.0
Other Non CA	497.0	580.0	607.0	634.0
Current Investments	628.0	641.0	701.0	761.0
Inventory	1,126.0	1,412.0	1,420.7	1,586.9
Debtors	388.0	652.0	710.4	762.9
Cash & Bank	944.0	579.0	649.5	402.9
Other CA	250.0	221.0	223.0	233.0
Total Current Assets	3,336.0	3,505.0	3,704.6	3,746.8
Creditors	1,134.0	1,344.0	1,278.6	1,373.3
Short Term Borrowings	340.0	345.0	360.0	375.0
Other Current Liabilities	539.0	464.0	479.0	494.0
Total Current Liabilities	2,013.0	2,153.0	2,117.6	2,242.3
Net Current Assets	1,323.0	1,352.0	1,587.0	1,504.5
Miscl. Exps. not w/o	0.0	0.0	0.0	0.0
Application of Funds	3497.0	3633.0	3576.0	3473.2

Source: Company, ICICI Direct Research

Exhibit 13: Key ratios				
(Year-end March)	FY21	FY22	FY23E	FY24E
Per share data (₹)				
EPS (Adjusted)	9.3	9.7	10.6	11.7
Cash EPS	10.4	10.8	11.8	13.1
BV	25.1	25.9	25.5	24.7
DPS	7.5	9.2	11.0	12.5
Cash Per Share	7.3	4.5	5.0	3.1
Operating Ratios (%)				
EBITDA Margin	19.8	17.7	18.3	18.9
PBT / Total Operating income	18.9	16.8	17.3	17.9
PAT Margin	14.9	13.2	13.2	13.6
Inventory dbcs	51	54	50	52
Debtor dbcs	18	25	25	25
Creditor dbcs	51	52	45	45
Return Ratios (%)				
RoE	37.0	37.5	41.4	47.4
RoCE	40.3	41.2	46.8	52.9
RoIC	68.0	61.8	66.1	70.2
Valuation Ratios (x)				
P/E	54.2	51.7	47.6	43.0
EV / EBITDA	40.1	38.1	33.8	30.6
EV / Net Sales	7.9	6.7	6.2	5.8
Market Cap / Sales	8.1	6.8	6.3	5.8
Price to Book Value	20.0	19.4	19.7	20.3
Solvency Ratios				
Debt/EBITDA	0.2	0.2	0.2	0.2
Debt / Equity	0.1	0.1	0.1	0.1
Current Ratio	1.4	1.6	1.7	1.8
Quick Ratio	0.8	0.8	0.9	0.9

Source: Company, ICICI Direct Research



	CMP	TP		M Cap	EPS (₹)				P/E (x)	Price/Sales (x)			(x)	RoCE (%)			RoE (%)		
	(₹)	(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Colgate (COLPAL)	1,581	1,575	Hold	37,937	38.5	40.8	45.0	41.1	38.7	35.2	7.4	6.8	6.2	109.6	112.7	116.7	84.9	86.6	89.7
Dabur India (DABIND)	511	680	Buy	93,515	9.9	11.6	13.0	51.8	44.0	39.2	8.6	7.8	7.0	24.9	25.5	26.4	20.8	22.5	22.8
Hindustan Unilever (HINLEV)	2,149	2,200	Hold	503,770	37.5	39.5	43.6	57.3	54.4	49.2	10.0	9.1	8.5	20.2	21.9	24.2	18.1	19.1	21.2
ITC Limited (ITC)	267	260	Hold	287,822	12.6	14.6	16.2	21.2	18.3	16.5	5.0	4.8	4.3	32.4	35.9	38.5	25.0	27.7	29.6
Jyothy Lab (JYOLAB)	148	150	Hold	5,133	4.2	6.2	6.5	34.9	23.8	22.7	2.3	2.2	2.0	19.1	26.6	28.0	16.5	23.1	23.7
Marico (MARLIM)	503	530	Hold	64,929	9.7	10.6	11.7	51.7	47.6	43.0	6.8	6.3	5.8	41.2	46.8	52.9	37.5	41.4	47.4
Nestle (NESIND)	16,995	19,050	Hold	175,243	222.4	252.9	291.6	76.4	67.2	58.3	12.0	10.8	9.8	58.7	58.8	62.9	111.3	110.4	111.8
Tata Consumer Products (TAT	765	910	Buy	71,514	11.0	15.0	17.5	69.4	51.1	43.8	5.8	5.2	4.8	8.4	10.3	11.3	7.0	8.8	9.8
VST Industries (VSTIND)	3,169	3,425	Hold	4,986	229.3	252.9	290.5	13.8	12.5	10.9	4.2	3.9	3.6	39.2	44.6	50.6	30.0	33.4	37.8
Varun Beverage (VARBEV)	1,076	1,300	Buy	45,860	17.2	25.9	30.3	62.4	41.6	35.5	5.2	4.2	3.8	17.1	25.6	29.7	18.3	22.8	23.0
Zydus Wellness (ZYDWEL)	1,628	2,200	Buy	10,819	51.4	62.6	73.0	31.7	26.0	22.3	5.3	4.8	4.3	6.7	8.0	9.1	6.9	8.3	9.4

Source: Bloomberg, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



ANALYST CERTIFICATION

I/We, Sanjay Manyal MBA (FINANCE) Research Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financia interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may o may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selecter recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we woult endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICIC Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information hereing is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by an recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or companies mentioned in the report during the period preceding the period prece

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the pastwelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or othe benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict o interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other materia conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.